Page 9 - Nuclear Export News Today

Redwood Wealth Management Group LLC acquired a new position in shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Rating) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 33,230 shares of the company’s stock, valued at approximately $113,000. Other hedge funds and other […]

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it...

Several Westminster College honors students will publicly defend their capstone research projects this spring, marking the end of nearly two years of high-level academic exploration. 

Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Rating) CEO Richard A. Paulson sold 3,497 shares of the company’s stock in a transaction dated Tuesday, April 4th. The stock was sold at an average price of $3.97, for a total transaction of $13,883.09. Following the completion of the transaction, the chief executive officer now owns 816,619 shares […]

NEWTON, Mass., April 3, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. , a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an... | April 3, 2023

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...

Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Rating) was the recipient of a large decline in short interest during the month of March. As of March 15th, there was short interest totalling 16,730,000 shares, a decline of 8.7% from the February 28th total of 18,330,000 shares. Based on an average daily volume of 2,760,000 shares, the […]

Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Rating) was the target of a large decline in short interest in the month of March. As of March 15th, there was short interest totalling 16,730,000 shares, a decline of 8.7% from the February 28th total of 18,330,000 shares. Based on an average daily trading volume, of 2,760,000 shares, […]

Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Rating) has received a consensus recommendation of “Moderate Buy” from the nine brokerages that are covering the company, Marketbeat.com reports. Three analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price objective among analysts that have […]

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...